Inhibition of angiotensin converting enzyme and potentiation of bradykinin by retro-inverse analogues of short peptides and sequences related to angiotensin I and bradykinin

Biochemical Pharmacology

Volumn 51, Issue 8, 1996, Pages 1051-1060

  Carmona, Adriana K ^a   Juliano, Luiz ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiotensin converting enzyme inhibitors; Bradykinin potentiation; Peptide synthesis; Retro inverso peptide

Indexed keywords

ANGIOTENSIN I DERIVATIVE; BRADYKININ; BRADYKININ DERIVATIVE; DIPEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; PEPTIDE DERIVATIVE; SNAKE VENOM; TRIPEPTIDE;

AMINO ACID COMPOSITION; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME BLOOD LEVEL; ENZYME INHIBITION; GUINEA PIG; HYDROLYSIS; ILEUM; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE CONTRACTILITY;

AMINO ACID SEQUENCE; ANGIOTENSIN I; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRADYKININ; DRUG SYNERGISM; GUINEA PIGS; ILEUM; MOLECULAR SEQUENCE DATA; MUSCLE CONTRACTION; PEPTIDES; PEPTIDYL-DIPEPTIDASE A; SNAKE VENOMS;

EID: 0029868276     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00047-0     Document Type: Article

References (46)

1. Sweet CS, Gross DM, Arbegast PT, Gaul SL, Britt PM, Ludden CT, Weitz D and Stone CA, Antihypertensive activity of N-[(S)]-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK 421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther 216: 558-566, 1981.
2. Marks ES, Bing RF, Thurston H and Swales JD, Vasodepressor property of the converting enzyme inhibitor captopril (SQ 14225): The role of factors other than renin-angiotensin blockade in the rat. Clin Sci 58: 1-6, 1980.
3. Antonaccio MJ, Harris D, Goldenberg H, High JP and Rubin B, The effects of captopril, propranolol, and indomethacin on blood pressure and plasma renin activity in spontaneously hypertensive and normotensive rats. Proc Soc Exp Biol Med 162: 429-433, 1979.
4. Murthy VS, Waldron TL, Goldenberg ME and Vollmer RR, Inhibition of angiotensin converting enzyme by SQ 14225 in conscious rabbits. Eur J Pharmacol 46: 207-212, 1977.
5. Mak IT, Freedman AM, Dickens BF and Weglicki WB, Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 40: 2169-2175, 1990.
6. Oparil S, Koerner T and O'Donoghue JK, Mechanism of angiotensin I converting enzyme inhibition by SQ 20881 (
7. Waeber B, Brunner HR, Brunner DB, Curtet AL, Turini GA and Gavras H, Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension 2: 236-242, 1980.
8. Lindsey CJ, De Paula UM and Paiva ACM, Protracted effect of converting enzyme inhibition on the rat's response to intraarterial bradykinin. Hypertension 5 (Suppl V): V134-V137, 1983.
9. Bendhack LM, Lindsey CJ and Paiva ACM, Converting enzyme inhibitors decrease kininase but not converting activity in the rat mesenteric vascular bed. Hypertension 8 (Suppl I): I,90-I-94, 1986.
10. Sabia EB, Tominaga M, Paiva ACM and Piazza TB, Bradykinin potentiating and sensitizing activities of new synthetic analogues of snake venom peptides. J Med Chem 20: 1679-1681, 1977.
11. Schaffel R, Rodrigues MS and Assreuy J, Potentiation of bradykinin effects and inhibition of kininase activity in isolated smooth muscle. Can J Physiol Pharmacol 69: 904-908, 1990.
12. Campbell DJ, Kladis A and Ducan AM, Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23: 439-449, 1994.
13. Gohlke P, Bunning P, Bonner G and Unger TH, ACE inhibitor effect on bradykinin metabolism in the vascular wall. In: Recent Progress on Kinins: Pharmacological and Clinical Aspects of the Kallikrein-Kinin System, Part II (Eds. Bönner G, Fritz H, Schoelkens B, Dietze G and Luppertz K), pp. 178-185. Birkhäuser, Basel, 1992.
14. Camargo ACM and Ferreira SH, Action of bradykinin potentiating factor (BFP) and dimercaprol (BAL) on the responses to bradykinin of isolated preparations of rat intestines. Br J Pharmacol 42: 305-307, 1971.
15. Greene LJ, Camargo ACM, Krieger EM, Stewart JM and Ferreira SH, Inhibition of the conversion of angiotensin I to II and potentiation of bradykinin by small peptides present in Bothrops jararaca venom. Circ Res 30/31 (Suppl II): II-62-II-71, 1972.
16. Hecker M, Porsti I, Bara AT and Bussi R, Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: Interaction at the receptor level. Br J Pharmacol 111: 238-244, 1994.
17. Auch-Schwelk W, Bossaller C, Claus M, Graf K, Gräfe M and Fleck E, ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res 27: 312-317, 1993.
18. Verdini AS and Viscome GC, Synthesis, resolution, and assignment of configuration of potent hypotensive retro-inverso bradykinin potentiating peptide 5a (BPP 5a) analogues. J Chem Soc Perkin Trans I: 697-701, 1985.
19. Bonelly F, Pessi A and Verdini AS, Solid phase synthesis of retro-inverso peptide analogues. Int J Pept Protein Res 24: 553-556, 1984.
20. Schechter I and Berger A, On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27: 157-162, 1967.
21. Goodman M and Chorev M, On the concept of linear modified retro-peptide structures. Acc Chem Res 12: 1-7, 1979.
22. Chorev M and Goodman M, A dozen years of retro-inverso peptidomimetics. Acc Chem Res 26: 266-273, 1993.
23. Cheung H-S, Wang F-L, Ondetti MA, Sabo EF and Cushman DW, Binding of peptide substrates and inhibitors of angiotensin-converting enzyme. Importance of COOH-terminal dipeptide sequence. J Biol Chem 255: 401-407, 1980.
24. Nakaie CR, Oliveira MCF, Juliano L and Paiva ACM, Inhibition of renin by conformationally restricted analogues of angiotensinogen. Biochem J 205: 43-47, 1982.
25. Ferreira SH, Bartelt DC and Greene LJ, Isolation of bradykinin potentiating peptides from Bothrops jararaca venom. Biochemistry 9: 2583-2593, 1970.
26. Kato H and Suzuki T, Bradykinin-potentiating peptides from the venom of Agkistrodon halys blomhoffii. Isolation of five bradykinin potentiators and the amino acid sequences of two of them, potentiators B and C. Biochemistry 10: 972-980, 1971.
27. Stewart JM and Young JD, Solid Phase Peptide Synthesis. WH Freeman Co., San Francisco, CA, 1969.
28. Juliano MA and Juliano L, Synthesis and kinetic parameters of hydrolysis by trypsin of some acyl-arginyl-p-nitroanilides and peptides containing arginyl-p-nitroanilide. Braz J Med Biol Res 18: 435-445, 1985.
29. Hirata IY, Boschcov P, Oliveira MCF, Juliano MA, Miranda A, Chagas JR, Tsuboi S, Okada Y and Juliano L, Synthesis of human angiotensinogen (1-17) containing one of the putative glycosylation binding sites and its hydrolysis by human renin and porcine pepsin. Int J Pept Protein Res 38: 298-307, 1991.
30. Chagas JR, Hirata IY, Juliano MA, Xiong W, Wang C, Chao J, Juliano L and Prado ES, Substrate specificities of tissue kallikrein and T-kininogenase: Their possible role in kininogen processing. Biochemistry 31: 4969-4974, 1992.
31. Greenstein JP and Winitz M, Chemical procedures for the synthesis of peptides. Chemistry of the Amino Acids, Vol. 2, pp. 763-1295. John Wiley, New York, 1961.
32. Bergmann M and Zervas L, A method for the stepwise degradation of polypeptides. J Biol Chem 113: 341-357, 1936.
33. Goissis G, Nouaihetas VLA and Paiva ACM, Synthesis of biologically active retroenantiomers of angiotensin peptides. J Med Chem 19: 1287-1290, 1976.
34. Spector T, Refinement of the Coomassie blue method of protein quantitation. Anal Biochem 86: 142-146, 1978.
35. Laemmli UK, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
36. Cushman DW and Cheung HS, Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 20: 1637-1648, 1971.
37. Friedland F and Silverstein F, A sensitive fluorimetric assay for serum angiotensin converting enzyme. Am J Clin Pathol 66: 416-424, 1976.
38. Yang HYT, Erdös EG and Levin Y, Characterization of a dipeptidyl hydrolase (kinin II; angiotensin I converting enzyme). J Pharmacol Exp Ther 117: 291-300, 1971.
39. Leatherbarrow RJ, Grafit Version 3.0. Erithacus Software Ltd., Staines, U.K., 1992.
40. Tominaga M, Stewart JM, Paiva TB and Paiva ACM, Synthesis and properties of new bradykinin potentiating peptides. J Med Chem 18: 130-133, 1975.
41. Ibarra-Rubio MH, Pena JC and Pedraza-Chaverri J, Kinetic and inhibitory characteristics of serum angiotensin-converting enzyme from nine mammalian species. Comp Biochem Physiol [B] 92: 339-403, 1989.
42. Lanzillo JJ and Fanburg BL, Angiotensin I-converting enzyme from guinea pig lung and serum. A comparison of some kinetic and inhibition properties. Biochim Biophys Acta 445: 161-168, 1976.
43. Harris RB, Ohlsson JT and Wilson IB, Purification of human serum angiotensin I converting enzyme by affinity chromatography. Anal Biochem 111: 227-234, 1981.
44. Chorev M, MacDonald SA and Goodman M, Retro-inverso isomerization of peptides: Side reactions in the synthesis of N-N′-diacyl-1,1-diamino-2-phenylethane derivatives. J Org Chem 49: 821-827, 1984.
45. Rohrbach MS, Williams EB and Rolstad DA, Purification and substrate specificity of bovine angiotensin-converting enzyme. J Biol Chem 256: 225-230, 1981.
46. Ondetti MA and Chusman DW, Angiotensin-converting enzyme inhibitors: Biochemical properties and biological actions. Crit Rev Biochem 16: 381-411, 1984.